279 related articles for article (PubMed ID: 20370712)
1. GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity?
Nevalainen T; Irving AJ
Curr Top Med Chem; 2010; 10(8):799-813. PubMed ID: 20370712
[TBL] [Abstract][Full Text] [Related]
2. The G protein-coupled receptor 55 ligand l-α-lysophosphatidylinositol exerts microglia-dependent neuroprotection after excitotoxic lesion.
Kallendrusch S; Kremzow S; Nowicki M; Grabiec U; Winkelmann R; Benz A; Kraft R; Bechmann I; Dehghani F; Koch M
Glia; 2013 Nov; 61(11):1822-31. PubMed ID: 24038453
[TBL] [Abstract][Full Text] [Related]
3. Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands.
Kapur A; Zhao P; Sharir H; Bai Y; Caron MG; Barak LS; Abood ME
J Biol Chem; 2009 Oct; 284(43):29817-27. PubMed ID: 19723626
[TBL] [Abstract][Full Text] [Related]
4. Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids.
Anavi-Goffer S; Baillie G; Irving AJ; Gertsch J; Greig IR; Pertwee RG; Ross RA
J Biol Chem; 2012 Jan; 287(1):91-104. PubMed ID: 22027819
[TBL] [Abstract][Full Text] [Related]
5. GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors.
Zhao P; Abood ME
Life Sci; 2013 Mar; 92(8-9):453-7. PubMed ID: 22820167
[TBL] [Abstract][Full Text] [Related]
6. GPR55 ligands promote receptor coupling to multiple signalling pathways.
Henstridge CM; Balenga NA; Schröder R; Kargl JK; Platzer W; Martini L; Arthur S; Penman J; Whistler JL; Kostenis E; Waldhoer M; Irving AJ
Br J Pharmacol; 2010 Jun; 160(3):604-14. PubMed ID: 20136841
[TBL] [Abstract][Full Text] [Related]
7. Lysophosphatidylinositol causes neurite retraction via GPR55, G13 and RhoA in PC12 cells.
Obara Y; Ueno S; Yanagihata Y; Nakahata N
PLoS One; 2011; 6(8):e24284. PubMed ID: 21904624
[TBL] [Abstract][Full Text] [Related]
8. Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells.
Oka S; Kimura S; Toshida T; Ota R; Yamashita A; Sugiura T
J Biochem; 2010 May; 147(5):671-8. PubMed ID: 20051382
[TBL] [Abstract][Full Text] [Related]
9. Modulation of l-α-lysophosphatidylinositol/GPR55 MAP kinase signalling by CB2 receptor agonists: identifying novel GPR55 inhibitors.
Anavi-Goffer S; Irving AJ; Ross RA
J Basic Clin Physiol Pharmacol; 2016 May; 27(3):303-10. PubMed ID: 27089417
[TBL] [Abstract][Full Text] [Related]
10. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo.
Whyte LS; Ryberg E; Sims NA; Ridge SA; Mackie K; Greasley PJ; Ross RA; Rogers MJ
Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16511-6. PubMed ID: 19805329
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of GPR55, a putative cannabinoid receptor.
Sharir H; Abood ME
Pharmacol Ther; 2010 Jun; 126(3):301-13. PubMed ID: 20298715
[TBL] [Abstract][Full Text] [Related]
12. The actions and metabolism of lysophosphatidylinositol, an endogenous agonist for GPR55.
Yamashita A; Oka S; Tanikawa T; Hayashi Y; Nemoto-Sasaki Y; Sugiura T
Prostaglandins Other Lipid Mediat; 2013 Dec; 107():103-16. PubMed ID: 23714700
[TBL] [Abstract][Full Text] [Related]
13. What is the natural ligand of GPR55?
Okuno T; Yokomizo T
J Biochem; 2011 May; 149(5):495-7. PubMed ID: 21324983
[TBL] [Abstract][Full Text] [Related]
14. GPR55-dependent stimulation of insulin secretion from isolated mouse and human islets of Langerhans.
Liu B; Song S; Ruz-Maldonado I; Pingitore A; Huang GC; Baker D; Jones PM; Persaud SJ
Diabetes Obes Metab; 2016 Dec; 18(12):1263-1273. PubMed ID: 27561953
[TBL] [Abstract][Full Text] [Related]
15. Regulation of GPR55 in rat white adipose tissue and serum LPI by nutritional status, gestation, gender and pituitary factors.
Imbernon M; Whyte L; Diaz-Arteaga A; Russell WR; Moreno NR; Vazquez MJ; Gonzalez CR; Díaz-Ruiz A; Lopez M; Malagón MM; Ross RA; Dieguez C; Nogueiras R
Mol Cell Endocrinol; 2014 Mar; 383(1-2):159-69. PubMed ID: 24378736
[TBL] [Abstract][Full Text] [Related]
16. The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation.
Henstridge CM; Balenga NA; Ford LA; Ross RA; Waldhoer M; Irving AJ
FASEB J; 2009 Jan; 23(1):183-93. PubMed ID: 18757503
[TBL] [Abstract][Full Text] [Related]
17. Lysophosphatidylinositol Promotes Chemotaxis and Cytokine Synthesis in Mast Cells with Differential Participation of GPR55 and CB2 Receptors.
Martínez-Aguilar LM; Ibarra-Sánchez A; Guerrero-Morán DJ; Macías-Silva M; Muñoz-Bello JO; Padilla A; Lizano M; González-Espinosa C
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047288
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors.
Irving A; Abdulrazzaq G; Chan SLF; Penman J; Harvey J; Alexander SPH
Adv Pharmacol; 2017; 80():223-247. PubMed ID: 28826536
[TBL] [Abstract][Full Text] [Related]
19. GPR55 - a putative "type 3" cannabinoid receptor in inflammation.
Yang H; Zhou J; Lehmann C
J Basic Clin Physiol Pharmacol; 2016 May; 27(3):297-302. PubMed ID: 26669245
[TBL] [Abstract][Full Text] [Related]
20. Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55.
Henstridge CM; Balenga NA; Kargl J; Andradas C; Brown AJ; Irving A; Sanchez C; Waldhoer M
Mol Endocrinol; 2011 Nov; 25(11):1835-48. PubMed ID: 21964594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
